Drug Profile
Research programme: heat shock protein 90 inhibitors - Merck & Co
Alternative Names: ARQ-250RP; Hsp90-inhibitorsLatest Information Update: 20 Jan 2020
Price :
$50
*
At a glance
- Originator ArQule
- Developer Merck & Co
- Class Small molecules
- Mechanism of Action HSP90 heat-shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jan 2020 ArQule has been acquired and merged into Merck & Co
- 07 Jul 2006 Preclinical trials in Cancer in USA (unspecified route)